AbbVie to Acquire Apogee Therapeutics for $10.9 Billion

Pharmaceutical giant AbbVie has reached a definitive agreement to acquire Apogee Therapeutics in a deal valued at approximately $10.9 billion. This strategic acquisition is intended to bolster AbbVie's immunology drug pipeline by integrating Apogee's clinical-stage assets. The transaction is anticipated to conclude in the third quarter of 2026, pending regulatory approvals.